Innoviva ROA 2012-2026 | INVA
Current and historical return on assets (ROA) values for Innoviva (INVA) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Innoviva ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2026-03-31 | $0.51B | $1.56B | 32.40% |
| 2025-12-31 | $0.27B | $1.41B | 19.18% |
| 2025-09-30 | $0.13B | $1.33B | 9.55% |
| 2025-06-30 | $0.04B | $1.28B | 2.97% |
| 2025-03-31 | $-0.06B | $1.25B | -4.87% |
| 2024-12-31 | $0.02B | $1.26B | 1.83% |
| 2024-09-30 | $0.07B | $1.24B | 5.23% |
| 2024-06-30 | $0.15B | $1.23B | 11.86% |
| 2024-03-31 | $0.18B | $1.21B | 15.11% |
| 2023-12-31 | $0.18B | $1.17B | 15.38% |
| 2023-09-30 | $0.05B | $1.17B | 4.29% |
| 2023-06-30 | $0.23B | $1.20B | 19.47% |
| 2023-03-31 | $0.23B | $1.21B | 19.39% |
| 2022-12-31 | $0.22B | $1.20B | 17.90% |
| 2022-09-30 | $0.29B | $1.13B | 26.05% |
| 2022-06-30 | $0.10B | $1.02B | 9.76% |
| 2022-03-31 | $0.19B | $0.93B | 20.17% |
| 2021-12-31 | $0.27B | $0.92B | 28.73% |
| 2021-09-30 | $0.31B | $0.94B | 32.84% |
| 2021-06-30 | $0.27B | $0.95B | 27.90% |
| 2021-03-31 | $0.25B | $0.97B | 26.02% |
| 2020-12-31 | $0.22B | $0.90B | 24.96% |
| 2020-09-30 | $0.22B | $0.83B | 26.06% |
| 2020-06-30 | $0.23B | $0.77B | 29.72% |
| 2020-03-31 | $0.19B | $0.71B | 26.70% |
| 2019-12-31 | $0.16B | $0.66B | 24.00% |
| 2019-09-30 | $0.38B | $0.61B | 61.24% |
| 2019-06-30 | $0.38B | $0.52B | 74.44% |
| 2019-03-31 | $0.40B | $0.44B | 91.17% |
| 2018-12-31 | $0.40B | $0.36B | 109.85% |
| 2018-09-30 | $0.19B | $0.32B | 60.27% |
| 2018-06-30 | $0.17B | $0.34B | 48.62% |
| 2018-03-31 | $0.15B | $0.35B | 41.79% |
| 2017-12-31 | $0.13B | $0.38B | 35.22% |
| 2017-09-30 | $0.10B | $0.38B | 26.34% |
| 2017-06-30 | $0.09B | $0.38B | 24.31% |
| 2017-03-31 | $0.07B | $0.38B | 18.95% |
| 2016-12-31 | $0.06B | $0.38B | 15.57% |
| 2016-09-30 | $0.04B | $0.39B | 9.83% |
| 2016-06-30 | $0.02B | $0.40B | 4.46% |
| 2016-03-31 | $-0.01B | $0.42B | -1.18% |
| 2015-12-31 | $-0.02B | $0.45B | -4.45% |
| 2015-09-30 | $-0.04B | $0.48B | -8.37% |
| 2015-06-30 | $-0.06B | $0.51B | -11.05% |
| 2015-03-31 | $-0.11B | $0.54B | -20.64% |
| 2014-12-31 | $-0.17B | $0.57B | -29.56% |
| 2014-09-30 | $-0.20B | $0.61B | -33.20% |
| 2014-06-30 | $-0.23B | $0.64B | -35.81% |
| 2014-03-31 | $-0.20B | $0.64B | -31.57% |
| 2013-12-31 | $-0.17B | $0.63B | -26.84% |
| 2013-09-30 | $-0.15B | $0.56B | -27.18% |
| 2013-06-30 | $-0.14B | $0.49B | -28.66% |
| 2013-03-31 | $-0.14B | $0.44B | -32.11% |
| 2012-12-31 | $-0.02B | $0.34B | -5.26% |
| 2012-09-30 | $-0.02B | $0.32B | -7.62% |
| 2012-06-30 | $-0.02B | $0.29B | -6.90% |
| 2012-03-31 | $-0.01B | $0.27B | -3.01% |
| 2011-12-31 | $-0.12B | $0.29B | -40.00% |
| 2011-09-30 | $-0.10B | $0.31B | -31.82% |
| 2011-06-30 | $-0.09B | $0.29B | -30.29% |
| 2011-03-31 | $-0.08B | $0.27B | -30.80% |
| 2010-12-31 | $-0.08B | $0.26B | -32.75% |
| 2010-09-30 | $-0.09B | $0.22B | -39.73% |
| 2010-06-30 | $-0.09B | $0.21B | -41.61% |
| 2010-03-31 | $-0.09B | $0.21B | -43.41% |
| 2009-12-31 | $-0.09B | $0.20B | -43.31% |
| 2009-09-30 | $-0.08B | $0.21B | -37.62% |
| 2009-06-30 | $-0.08B | $0.23B | -34.21% |
| 2009-03-31 | $-0.08B | $0.25B | -33.64% |
| 2008-12-31 | $-0.09B | $0.27B | -35.07% |
| 2008-09-30 | $-0.11B | $0.25B | -44.49% |
| 2008-06-30 | $-0.12B | $0.24B | -51.80% |
| 2008-03-31 | $-0.14B | $0.22B | -64.44% |
| 2007-12-31 | $-0.16B | $0.20B | -77.85% |
| 2007-09-30 | $-0.16B | $0.23B | -71.54% |
| 2007-06-30 | $-0.17B | $0.25B | -67.33% |
| 2007-03-31 | $-0.17B | $0.28B | -59.23% |
| 2006-12-31 | $-0.17B | $0.30B | -55.33% |
| 2006-09-30 | $-0.17B | $0.29B | -58.47% |
| 2006-06-30 | $-0.17B | $0.27B | -63.67% |
| 2006-03-31 | $-0.16B | $0.25B | -65.51% |
| 2005-12-31 | $-0.14B | $0.23B | -62.51% |
| 2005-09-30 | $-0.13B | $0.24B | -53.28% |
| 2005-06-30 | $-0.11B | $0.25B | -46.34% |
| 2005-03-31 | $-0.11B | $0.19B | -59.73% |
| 2004-12-31 | $-0.10B | $0.12B | -83.10% |
| 2004-09-30 | $-0.09B | $0.05B | -175.61% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |